Investigational drug · Phase 2
BMX-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "BMX-001"
First trial start
2025
Apr 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMX-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Neoplasms
- Endometrial Cancer, Endometrial Neoplasm
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMX-001" as an intervention, largest first.
- Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001Pivotal-lookingCompleted
BioMimetix JV, LLCIndustry
NCT02655601 · 177 participants · Start Sep 25, 2018 · Primary completion Aug 17, 2023
Drug: BMX-001; Temozolomide · For: High Grade Glioma; Astrocytoma, Grade III; Glioblastoma
Sites: Birmingham, Alabama; San Francisco, California; Lexington, Kentucky · 9 sites in all
- Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001Pivotal-lookingRecruiting
University of NebraskaAcademic, hospital or other
NCT05254327 · 118 participants (planned) · Start Aug 15, 2022 · Primary completion May 2030
Drug: BMX-001 · For: Rectal Cancer
Sites: Lexington, Kentucky; Omaha, Nebraska; San Antonio, Texas
NRG OncologyAcademic, hospital or other
NCT06532279 · 98 participants (planned) · Start Jun 23, 2025 · Primary completion Jan 1, 2027
Drug: Cisplatin; MnSOD Mimetic BMX-001 and 1 more · For: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 and 38 more
Sites: Gilbert, Arizona; Peoria, Arizona; Phoenix, Arizona · 153 sites in all
BioMimetix JV, LLCIndustry
NCT03608020 · 35 participants · Start Oct 4, 2018 · Primary completion Dec 31, 2023
Drug: BMX-001 · For: Multiple Brain Metastases
Sites: Lexington, Kentucky; Detroit, Michigan; Durham, North Carolina · 4 sites in all
BioMimetix JV, LLCIndustry
NCT02990468 · 29 participants · Start Apr 19, 2017 · Primary completion Feb 21, 2020
Drug: BMX-001; Cisplatin · For: Head and Neck Cancer
Sites: San Francisco, California; Gainesville, Florida; Omaha, Nebraska · 4 sites in all
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial CancerNot yet recruiting
BioMimetix JV, LLCIndustry
NCT06620029 · 27 participants (planned) · Start Apr 1, 2025 · Primary completion Mar 31, 2027
Drug: BMX-001; Paclitaxel (Taxol) · For: Ovarian Neoplasms; Endometrial Cancer, Endometrial Neoplasm
Sites: Durham, North Carolina
- Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal CancerActive, not recruiting
University of NebraskaAcademic, hospital or other
NCT03386500 · 24 participants · Start Nov 28, 2017 · Primary completion Oct 2026
Drug: BMX-001 · For: Anal Cancer, Squamous Cell Carcinoma; Radiation Exposure
Sites: Omaha, Nebraska
BioMimetix JV, LLCIndustry
NCT04607642 · 0 participants · Start Jul 2021 · Primary completion Jul 2023
Drug: BMX-001; Cisplatin · For: Head and Neck Cancer
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I/II Trial of the Metalloporphyrin Radioprotectant BMX-001 in Patients with Newly Diagnosed Head and Neck Cancer Receiving Concurrent Radiation Therapy and Cisplatin.
Salans M, Yom SS, Dufault SM, et al. · Int J Radiat Oncol Biol Phys 2026
- BMX-001 acts as a selective chemoradioprotector in rectal cancer.
Myers MS, Kosmacek EA, Liew CS, et al. · Redox Biochem Chem 2026
- BMX-001, a clinically relevant radioprotector, can reverse radiation-induced fibrosis when given three weeks after radiation, in part, by restoring methylation.
Myers MS, Kosmacek EA, Liew CS, et al. · Redox Biol 2026
- Correction: Pan et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159.
Pan T, Alimi OA, Liu B, et al. · Pharmaceuticals (Basel) 2026
- Suppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP5+ (BMX-001).
Spasojevic I, Huang Z, da Silva WTA, et al. · Oxid Med Cell Longev 2025
- Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.
Pan T, Alimi OA, Liu B, et al. · Pharmaceuticals (Basel) 2025
Also in development for Ovarian Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Mocertatug rezetecanMo-RezPhase 36 trials
GSK · Ovarian Neoplasms, Neoplasms, Endometrial, Tumours, Gynecological
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- VB15010Phase 21 trial
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Cancer, Neoplasms, Neoplasms, Breast
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.